141 related articles for article (PubMed ID: 22484635)
1. Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement.
Navajas A; Lassaletta A; Morales A; López-Ibor B; Sábado C; Moscardó C; Mateos E; Molina J; Sagaseta M; Sastre A
Clin Transl Oncol; 2012 Apr; 14(4):280-6. PubMed ID: 22484635
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
Mastronuzzi A; Del Bufalo F; Iacono A; Secco DE; Serra A; Colafati GS; DE Ioris MA; Corsetti T
Anticancer Res; 2013 Aug; 33(8):3515-8. PubMed ID: 23898128
[TBL] [Abstract][Full Text] [Related]
3. [Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents].
Moreno L; García Ariza MA; Cruz O; Calvo C; Fuster JL; Salinas JA; Moscardo C; Portugal R; Merino JM; Madero L
An Pediatr (Barc); 2016 Nov; 85(5):274.e1-274.e8. PubMed ID: 27086069
[TBL] [Abstract][Full Text] [Related]
4. Liposomal cytarabine for central nervous system embryonal tumors in children and young adults.
Partap S; Murphy PA; Vogel H; Barnes PD; Edwards MS; Fisher PG
J Neurooncol; 2011 Jul; 103(3):561-6. PubMed ID: 20859651
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
6. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Passarin MG; Moretto G; Musso AM; Ottaviani S; Masotto B; Ghimenton C; Iuzzolino P; Buffone E; Rudà R; Soffietti R; Vattemi E; Pedersini R
J Neurooncol; 2010 May; 97(3):439-44. PubMed ID: 19876600
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
9. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP; Castañón E; Carranza OE; Zubiri L; Martín P; Espinós J; Rodríguez J; Santisteban M; Aramendía JM; Gil-Bazo I
J Neurooncol; 2013 Dec; 115(3):429-35. PubMed ID: 24037499
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy.
Niwińska A; Rudnicka H; Murawska M
Clin Breast Cancer; 2015 Feb; 15(1):66-72. PubMed ID: 25287959
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child.
Lassaletta A; Perez-Olleros P; Scaglione C; Sirvent S; De Prada I; Perez-Martinez A; Ruiz-Hernandez A; Madero L
J Neurooncol; 2007 Jul; 83(3):303-6. PubMed ID: 17245619
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.
Lassaletta A; Lopez-Ibor B; Mateos E; Gonzalez-Vicent M; Perez-Martinez A; Sevilla J; Diaz MA; Madero L
J Neurooncol; 2009 Oct; 95(1):65-69. PubMed ID: 19381444
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
16. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N; Hartog CM; Bassan R; Derigs HG; Dombret H; Greil R; Hernández-Rivas JM; Huguet F; Intermesoli T; Jourdan E; Junghanss C; Leimer L; Moreno MJ; Reichle A; Ribera J; Schmid M; Serve H; Stelljes M; Stuhlmann R; Hoelzer D;
Haematologica; 2011 Feb; 96(2):238-44. PubMed ID: 20952517
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Chamberlain MC
J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
Parasole R; Menna G; Marra N; Petruzziello F; Locatelli F; Mangione A; Misuraca A; Buffardi S; Di Cesare-Merlone A; Poggi V
Leuk Lymphoma; 2008 Aug; 49(8):1553-9. PubMed ID: 18766969
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
